Table 4.
Three-months persistence of stroke secondary prevention medications.
| Control group (N = 277) | Intervention group (N = 365) | Statistic | P | |
|---|---|---|---|---|
| Overall persistence, n (%) | 201 (72.6) | 303 (83.0) | 10.192 | 0.001 |
| Antiplatelet agents | ||||
| At discharge | 271 | 354 | ||
| 3 months, n (%) | 250 (92.3) | 340 (96.1) | 4.180 | 0.041 |
| Antihypertensive agents | ||||
| At discharge | 124 | 143 | ||
| 3 months, n (%) | 109 (87.9) | 123 (86.0) | 0.208 | 0.648 |
| Statins | ||||
| At discharge | 257 | 354 | ||
| 3 months, n (%) | 228 (88.7) | 337 (95.2) | 8.986 | 0.003 |
| Hypoglycemic agents | ||||
| At discharge | 70 | 94 | ||
| 3 months, n (%) | 43 (61.4) | 73 (77.7) | 5.106 | 0.024 |
At discharge, the number of patients taking the drug according to the doctor's advice at discharge; 3 months, the number and percentage of patients still using the drug at 3 months of follow-up after discharge.